MANNKIND CORP Prepaid Expense and Other Assets, Current
MANNKIND CORP (MNKD) had Prepaid Expense and Other Assets, Current of $46.96 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Prepaid Expense and Other Assets, Current $46.96M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $40.00M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $46.55M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $54.45M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $46.96M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $40.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $46.55M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $54.45M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $44.41M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $34.40M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $31.36M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $31.23M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $30.08M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $36.02M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $34.85M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $35.62M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $32.81M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $15.45M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $25.48M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $11.57M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $3.72M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $3.95M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $3.48M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $3.23M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $3.62M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $2.77M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $3.12M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $4.62M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $1.86M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $1.90M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $2.89M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $3.58M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $2.70M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $2.39M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $2.56M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $3.02M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $2.57M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $2.35M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.01M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $3.06M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $2.56M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $3.51M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $4.36M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $4.53M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $1.42M 10-Q/A · filed 2016-08-10 | |
| 2016-03-31 | $2.81M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $4.02M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $13.23M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $14.08M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $16.38M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $20.21M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $20.25M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $3.70M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $3.64M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $5.49M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $5.23M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $3.18M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $3.83M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $4.52M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $21.08M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $18.36M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $3.00M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $3.14M 10-K · filed 2013-03-18 | $2.63M 10-K · filed 2012-03-15 |
| 2011-09-30 | $2.96M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $1.59M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $2.85M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |